Last update: Dec. 8, 2017
Minimal risk for breastfeeding and infant.
An anti-enkephalin that decreases intestinal secretion.
Since the latest update, we have not found published data on its excretion in breast milk.
Its high percentage of protein binding makes it unlikely it will transfer to milk in significant quantities.
Possible side effects are not serious or frequent.
Its use is authorized in infants from 3 months of age (Pediamecum 2015)
Its indiscriminate use in treating gastroenteritis is not justified. Most cases of gastroenteritis do not require medication: good hydration is sufficient, even more so in the case of a breastfeeding mother.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM